Tilactase

Summary

Tilactase (CHEMBL2108793) is a phase-3 clinical-stage enzyme (ATC A09AA04); indicated across 1 condition including fabry disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Enzyme
• ATC class: A09AA04
• Indications: 1 condition
• Clinical trials: 1

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108793
Name	Tilactase
Type	Enzyme
Max phase	3
ATC	A09AA04

Also known as: Beta-galactosidase (aspergillus), G9S0VV191I, Galactosidase, Tilactasa, Tilactase, TILACTASE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
Fabry disease	3	MONDO:0010526	MONDO:0010526

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06630312	EARLY_PHASE1	COMPLETED	Glycemic Response of Whole Beans and Bean Products

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).